Page 105 - MEMOCiberesp014-ENG

Most relevant scientific articles
• Perise-Barrios a.J., JiMénez J.l., D’oMinguez-soto a., De la Mata F.J., CorBi a.l., góMez r. et al . Carbosilane dendrimers as gene delivery agents for the treatment of HIV infection . Journal of Controlled Release . 2014;184(1):51-57 .
• VaCas-CórDoBa e., CliMent n., De la Mata F.J., Plana M., góMez r., Pion M . et al . Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: Steps toward their clinical evaluation . Nanomedicine . 2014;9(17):2683-2702 .
• sÁnChez-roDríguez J., VaCas-CórDoBa e., góMez r., De la Mata F.J., Munoz-FernÁnDez Ma. A . Nanotech- derived topical microbicides for HIV prevention: The road to clinical development . Antiviral Research . 2014;113: 33-48 .
• sePulVeDa-CresPo D., lorente r., leal M., góMez r., De la Mata F.J., JiMénez J.l. et al . Synergistic acti- vity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antire- trovirals as topical anti-HIV-1 microbicide . Nanomedicine: Nanotechnology, Biology, and Medicine . 2014;10(3):609-618 .
Highlights
Institution: Servicio Madrileño de Salud Contact: Hospital Gregorio Marañón · C/ Ibiza 43, 28009 Madrid E-mail: mmunoz@gmail .com · Website: http://immunovirology .com
Along the year 2014 we took a great step in the use of nanotechnology in infectious diseases . We went from basic-clinical research to traslational research having developed a vaginal and rectal microbicide for topical application . We showed that our vaginal microbicide polianionic carbosilan dendrimers gel impeded 85% of HIV-1 infection in a humanized mouse model (BLT-mice) as a concept proof . We also showed that the combination of the polianionic carbosilan dendrimers with tenofovir or maraviroc, which work in the first steps of the HIV viral replication cycle as microbicide, stopped 100% the HIV-1 infections . This proved to be a breakthrough in our research not only in the use of dendrimers as micro- bicides, but also in the use of dendrimers as delivery systems, biodistribution, toxicology, etc in animal models . We also used these nanosytems as anti-latency drugs, nanovaccines and Ag presentation with dendritic cells . Finally, we established the in vitro and in vivo nanobioguided platform with the objective to test new nanosystems against other infectious diseases such as infections caused by HSV-2, HCV, Chijungunya, ebola . . .We got very promising results, showing how various dendrimers depending on their synthesis, nucleus, peripheral charges, generation, etc act against different virus . We have con- tributed to the development of new treatments against HIV-1, HSV-2 and HCV and to the search of potential cure for viral infections .
www .ciber-bbn .es 105